Advertisement
Advertisement
U.S. Markets open in 4 hrs 8 mins
Advertisement
Advertisement
Advertisement
Advertisement

Rubius Therapeutics, Inc. (RUBY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.2000-0.1000 (-7.69%)
At close: 04:00PM EDT
1.2000 0.00 (0.00%)
Pre-Market: 04:23AM EDT
Advertisement

Rubius Therapeutics, Inc.

399 Binney Street
Suite 300
Cambridge, MA 02139
United States
617 679 9600
https://www.rubiustx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees269

Key Executives

NameTitlePayExercisedYear Born
Mr. David R. Epstein B.Sc., M.B.A.Exec. Chairman495kN/A1962
Dr. Pablo J. Cagnoni M.D., Ph.D.CEO, Pres & Director971.45kN/A1963
Mr. Jose I. CarmonaCFO, Principal Accounting Officer & Treasurer659.2kN/A1972
Ms. Dannielle AppelhansChief Operating Officer422.98kN/A1983
Mr. Laurence A. Turka M.D.Chief Scientific Officer and Head of Research & Translational Medicine626.55kN/A1958
Ms. Maiken Keson-BrookesChief Legal Officer & Corp. Sec.607.74kN/A1973
Mr. Spencer FiskSr. VP & Chief Technical Operations OfficerN/AN/AN/A
Mr. Mark J. HernonChief Information OfficerN/AN/A1964
Ms. Lori MelanconChief Corp. Affairs OfficerN/AN/AN/A
Ms. Marissa HanifyDirector of Corp. CommunicationsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Rubius Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 8. The pillar scores are Audit: 7; Board: 8; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement